Corcept Therapeutics Investors May Lead Fraud Class Action Against Company
Opportunity for Corcept Therapeutics Shareholders
Corcept Therapeutics Incorporated (CORT) is facing serious allegations as its shareholders are urged to step forward to lead a potential securities fraud class action lawsuit. This comes following reports of substantial losses incurred by investors and lack of transparency from the company regarding significant regulatory issues with the FDA.
Background
On March 17, 2026, Glancy Prongay Wolke & Rotter LLP announced that investors who faced financial losses in their investment with Corcept Therapeutics may have the opportunity to take the lead in a securities fraud class action lawsuit. This follows a lawsuit filed against the company for failure to disclose critical information that could have influenced shareholders' investment decisions.
Allegations Against Corcept
The lawsuit claims that between October 31, 2024, and December 30, 2025, Corcept executives did not inform investors that:
1. The FDA had raised concerns regarding the adequacy of Corcept's program assessing relacorilant’s efficacy in treating hypertension related to hypercortisolism, along with questions about the pivotal
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.